EORTC 2387-SPRINT: The first pan-European TwiCs study has been activated
EORTC 2387-SPRINT: The first pan-European TwiCs study has been [...]
EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients
EORTC SPRINT clinical cancer study receives support from Rising [...]
Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort
Acute toxicity in patients with oligometastatic cancer following metastasis-directed [...]
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E²-RADIatE OligoCare study
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy [...]
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E²-RADIatE OligoCare cohort
Health-related quality of life in men with oligometastatic prostate [...]
ReCare: first site active
ReCare: first site active We [...]
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy [...]